Clinical utilization of blinatumomab in Chinese monocentric patients with relapsed or refractory B-cell acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Clinical utilization of blinatumomab in Chinese monocentric patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Published:2022-11-30 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Zhu Jingkui¹,Fan Jixin¹,Xie Tiantian¹,Zhao Haiqiu¹,Lu Runqing¹,Zhang Yinyin¹,Li Yingmei¹,Xie Xinsheng¹,Wan Dingming¹,Jiang Zhongxing¹,Song Yongping¹,He Fei¹,Guo Rong¹

Affiliation:

1. The First Affiliated Hospital of Zhengzhou University

Abstract

Abstract Purpose: Blinatumomab has promising applications in treating relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However, there are few studies on using blinatumomab for treating R/R B-ALL patients in China. Therefore, we evaluated the efficacy and safety of blinatumomab among Chinese R/R B-ALL patients. Methods: In total, 39 R/R B-ALL patients who received blinatumomab between October 2021 and August 2022 were selected as the study subjects. The primary endpoints include overall response rate (ORR) and complete minimal residual disease (MRD) response. Secondary endpoints included overall survival (OS) and adverse events (AEs). Results: The ORR and OS for 19 patients with less than 5% bone marrow (BM) blasts were 63.2% and 11 months (7.3–14.7), respectively. The median OS for the 20 patients was unavailable, and 17 (or 85%) had a full MRD response. Twenty-seven patients (69.2%) reported having at least 1 AE. Hematologic toxicity and infections were the most common AEs. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed on nine patients who had been remission-free for a long time. In the first month, one patient (11.1%) developed thrombotic microangiopathy associated with HSCT (TA-TMA) following transplantation. Conclusion: In R/R B-ALL patients, blinatumomab is an effective option in China.

Publisher

Research Square Platform LLC

Reference29 articles.

1. 1. Kiyoi, H. et al. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Sci 111, 1314–1323, doi:10.1111/cas.14322 (2020).

2. 2. Parker, C. et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376, 2009–2017, doi:10.1016/S0140-6736(10)62002-8 (2010).

3. 3. Brown, P. A. et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA 325, 833–842, doi:10.1001/jama.2021.0669 (2021).

4. 4. Jabbour, E. et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. The Lancet Haematology, doi:10.1016/s2352-3026(22)00285-x (2022).

5. 5. Srour, S. A. et al. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 23, 318–324, doi:10.1016/j.bbmt.2016.11.008 (2017).